IDH1-R132H was not detected by immunohistochemistry in 15 gliomas (12 WHO grade IV and three WHO grade III gliomas), while a positive IDH1-R132H status was observed in the remaining 15 gliomas (nine WHO grade II, five WHO grade III, and one WHO grade IV gliomas). This evidence concerns the gene IDH1 and central nervous system cancer.